

Cyramza[®] (ramucirumab) – New indication and boxed warning removal

- On May 13, 2019, [Eli Lilly announced](#) the FDA approval of [Cyramza \(ramucirumab\)](#), as a single agent, for the treatment of hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been treated with [Nexavar[®] \(sorafenib\)](#).
- Cyramza is also indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma, metastatic non-small cell lung cancer, and metastatic colorectal cancer.
- HCC is the most common form of liver cancer, comprising up to 90% of all cases. It is estimated that approximately 40% of all people with advanced HCC are AFP-High (AFP ≥ 400 ng/mL) and these patients are known to have a poorer prognosis relative to the general HCC patient population. Once patients who are AFP-High enter the second-line treatment setting, the expected survival is 3 to 5 months if untreated.
- The approval of Cyramza for the new indication was based on the placebo-controlled REACH-2 study of 292 patients with advanced HCC with AFP ≥ 400 ng/mL who had disease progression on or after prior Nexavar therapy or who were intolerant to Nexavar. Patients received Cyramza or placebo every 2 weeks until disease progression or unacceptable toxicity. The major efficacy outcome measure was overall survival (OS).
 - The median OS was 8.5 months in the Cyramza-treated patients vs. 7.3 months in the placebo group (hazard ratio [HR] = 0.71; 95% CI: 0.53, 0.95; $p = 0.020$).
 - The median progression-free survival was 2.8 months in the Cyramza-treated patients vs. 1.6 months in the placebo-group (HR = 0.45; 95% CI: 0.34, 0.60; $p < 0.0001$).
 - The overall response rate for the Cyramza-treated patients was 4.6% (95% CI: 1.7, 7.5) vs. 1.1% (95% CI: 0, 3.1) for the placebo group.
- In addition, the *Boxed Warning* for hemorrhage, gastrointestinal perforation, and impaired wound healing was removed from the Cyramza drug label.
 - The updated Cyramza labeling continues to provide important information on these specific risks in the *Warnings and Precautions* section of the drug label.
- The most common adverse reactions ($\geq 15\%$ and $\geq 2\%$ higher than placebo) with Cyramza use in HCC treated patients were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites.
- The most common laboratory abnormalities ($\geq 30\%$ and a $\geq 2\%$ difference in incidence between arms) with Cyramza use in HCC treated patients were thrombocytopenia, hypoalbuminemia, and hyponatremia.

- The recommended dose of Cyramza for HCC is 8 mg/kg every 2 weeks administered by intravenous infusion over 60 minutes. Cyramza should be continued until disease progression or unacceptable toxicity.
 - Consult the Cyramza drug label for dosing recommendations for all other indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.